Genotype-phenotype correlation for pulmonary function in cystic fibrosis

J de Gracia, F Mata, A Alvarez, T Casals, S Gatner, M Vendrell, D de la Rosa, L Guarner, E Hermosilla, J de Gracia, F Mata, A Alvarez, T Casals, S Gatner, M Vendrell, D de la Rosa, L Guarner, E Hermosilla

Abstract

Background: Since the CFTR gene was cloned, more than 1000 mutations have been identified. To date, a clear relationship has not been established between genotype and the progression of lung damage. A study was undertaken of the relationship between genotype, progression of lung disease, and survival in adult patients with cystic fibrosis (CF).

Methods: A prospective cohort of adult patients with CF and two CFTR mutations followed up in an adult cystic fibrosis unit was analysed. Patients were classified according to functional effects of classes of CFTR mutations and were grouped based on the CFTR molecular position on the epithelial cell surface (I-II/I-II, I-II/III-V). Spirometric values, progression of lung disease, probability of survival, and clinical characteristics were analysed between groups.

Results: Seventy four patients were included in the study. Patients with genotype I-II/I-II had significantly lower current spirometric values (p < 0.001), greater loss of pulmonary function (p < 0.04), a higher proportion of end-stage lung disease (p < 0.001), a higher risk of suffering from moderate to severe lung disease (odds ratio 7.12 (95% CI 1.3 to 40.5)) and a lower probability of survival than patients with genotype I-II/III, I-II/IV and I-II/V (p < 0.001).

Conclusions: The presence of class I or II mutations on both chromosomes is associated with worse respiratory disease and a lower probability of survival.

References

    1. Lancet. 2003 Feb 22;361(9358):681-9
    1. Science. 1989 Sep 8;245(4922):1066-73
    1. Am J Respir Crit Care Med. 2001 May;163(6):1331-7
    1. Chest. 2002 Jan;121(1):73-80
    1. Physiol Rev. 2002 Apr;82(2):503-68
    1. Med Clin (Barc). 2002 Nov 9;119(16):605-9
    1. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1359-71
    1. N Engl J Med. 1992 Apr 30;326(18):1187-91
    1. Cell. 1993 Jul 2;73(7):1251-4
    1. N Engl J Med. 1995 Jun 1;332(22):1475-80
    1. N Engl J Med. 1995 Jul 13;333(2):95-9
    1. Lancet. 1995 Jul 29;346(8970):274-6
    1. Pediatr Pulmonol. 1996 Dec;22(6):387-95
    1. Hum Mutat. 1997;9(4):332-8
    1. Hosp Pract (1995). 1997 Jun 15;32(6):115-8, 123-9, 134, passim
    1. Hum Genet. 1997 Dec;101(3):365-70
    1. J Med Genet. 1998 Feb;35(2):122-5
    1. J Pediatr. 1998 Apr;132(4):589-95
    1. Pediatrics. 1997 Sep;100(3):E5
    1. Thorax. 1998 Dec;53(12):1018-21
    1. FEBS Lett. 1999 Jun 11;452(3):371-4
    1. Lancet. 2003 May 17;361(9370):1671-6
    1. Ann Hum Genet. 2003 Sep;67(Pt 5):471-85
    1. Am J Respir Crit Care Med. 2003 Oct 15;168(8):918-51
    1. Clin Genet. 2004 Jun;65(6):490-5
    1. J Cyst Fibros. 2002 Mar;1(1):13-29
    1. Med Clin (Barc). 1984 Sep 29;83(9):392-3
    1. Thorax. 2000 Jun;55(6):459-62

Source: PubMed

3
購読する